

G-Ã Rivard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3765817/publications.pdf>

Version: 2024-02-01

70
papers

2,109
citations

279798

23
h-index

233421

45
g-index

70
all docs

70
docs citations

70
times ranked

1928
citing authors

#	ARTICLE	IF	CITATIONS
1	International workshop on immune tolerance induction: consensus recommendations. <i>Haemophilia</i> , 2007, 13, 1-22.	2.1	228
2	Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1228-1236.	3.8	224
3	Chitosan-glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defects. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 78-89.	1.3	207
4	Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. <i>Blood</i> , 2001, 98, 257-265.	1.4	116
5	An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. <i>Haemophilia</i> , 2012, 18, 962-970.	2.1	111
6	Bleeding risks associated with inheritance of the Quebec platelet disorder. <i>Blood</i> , 2004, 104, 159-165.	1.4	102
7	Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. <i>Blood</i> , 2010, 115, 1264-1266.	1.4	87
8	Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement Therapy. <i>Transfusion Science</i> , 1998, 19, 139-148.	0.6	73
9	Low-dose ASA Response Using the PFA-100 in Women With High-risk Pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009, 31, 1022-1027.	0.7	73
10	Circadian Time-Dependent Response of Childhood Lymphoblastic Leukemia to Chemotherapy: A Long-Term Follow-up Study of Survival. <i>Chronobiology International</i> , 1993, 10, 201-204.	2.0	57
11	Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. <i>Blood</i> , 2009, 113, 1543-1546.	1.4	49
12	Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1086-1094.	3.8	47
13	Immunoabsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. <i>Haemophilia</i> , 2003, 9, 711-716.	2.1	46
14	A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. <i>Haemophilia</i> , 2008, 14, 281-286.	2.1	45
15	Efficacy of factor VIII/von Willebrand factor concentrate Alphanate [®] in preventing excessive bleeding during surgery in subjects with von Willebrand disease. <i>Haemophilia</i> , 2008, 14, 271-275.	2.1	40
16	Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. <i>Blood</i> , 2009, 113, 1535-1542.	1.4	40
17	Management of acquired hemophilia A: Review of current evidence. <i>Transfusion and Apheresis Science</i> , 2018, 57, 717-720.	1.0	39
18	Canadian multi-institutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. <i>Haemophilia</i> , 2006, 12, 1-6.	2.1	38

#	ARTICLE	IF	CITATIONS
19	Quebec platelet disorder. Expert Review of Hematology, 2011, 4, 137-141.	2.2	34
20	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematology, the, 2018, 5, e252-e260.	4.6	31
21	Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010. Haemophilia, 2014, 20, 771-776.	2.1	29
22	Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?. Haemophilia, 2005, 11, 335-339.	2.1	27
23	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	2.1	24
24	Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. Thrombosis and Haemostasis, 2012, 107, 726-734.	3.4	19
25	Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. Haemophilia, 2013, 19, 449-455.	2.1	19
26	The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes. PLoS ONE, 2017, 12, e0173991.	2.5	18
27	Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. Frontiers in Medicine, 2020, 7, 358.	2.6	17
28	Asparaginase lowers plasma antithrombin and mannan-binding lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2015, 62, 1381-1387.	1.5	16
29	Management of acquired von Willebrand syndrome. Transfusion and Apheresis Science, 2018, 57, 721-723.	1.0	16
30	Alloantibody developed in a factor XIII A subunit deficient patient during substitution therapy; characterization of the antibody. Haemophilia, 2016, 22, 268-275.	2.1	15
31	Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a RUNX1 frameshift mutation. Haemophilia, 2017, 23, e204-e213.	2.1	14
32	Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors. BMC Research Notes, 2019, 12, 291.	1.4	14
33	Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS). Haemophilia, 2015, 21, 469-476.	2.1	13
34	Challenges on the diagnostic approach of inherited platelet function disorders: Is a paradigm change necessary?. Platelets, 2018, 29, 148-155.	2.3	13
35	Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. Frontiers in Immunology, 2018, 9, 2183.	4.8	13
36	Enhancer-gene rewiring in the pathogenesis of Quebec Platelet Disorder. Blood, 2020, 136, 2679-2690.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Relapse pattern and long-term outcomes in subjects with acquired haemophilia A. <i>Haemophilia</i> , 2019, 25, 252-257.	2.1	11
38	The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole <i>F8</i> gene sequencing and functional assays. <i>Haemophilia</i> , 2020, 26, 1056-1063.	2.1	11
39	Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7869.	4.1	11
40	The <i>GBA</i> p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies. <i>Clinical Genetics</i> , 2018, 94, 339-345.	2.0	9
41	Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 449-463.	1.7	9
42	Effect of chitosan and coagulation factors on the wound repair phenotype of bioengineered blood clots. <i>International Journal of Biological Macromolecules</i> , 2017, 104, 1916-1924.	7.5	8
43	The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in vitro model for therapeutic angioedema agents. <i>Life Sciences</i> , 2016, 155, 180-188.	4.3	6
44	Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 160-163.	0.7	6
45	Effect of a Rapidly Degrading Presolidified 10 kDa Chitosan/Blood Implant and Subchondral Marrow Stimulation Surgical Approach on Cartilage Resurfacing in a Sheep Model. <i>Cartilage</i> , 2017, 8, 417-431.	2.7	6
46	Synthetic anionic surfaces can replace microparticles in stimulating burst coagulation of blood plasma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 175, 596-605.	5.0	6
47	Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A. <i>BMC Hematology</i> , 2016, 16, 26.	2.6	5
48	A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor <i>VIII</i> . <i>Haemophilia</i> , 2018, 24, 236-244.	2.1	5
49	Antithrombin and fibrinogen levels as predictors for plasma asparaginase activity in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27729.	1.5	5
50	In Vitro Modeling of Bradykinin-Mediated Angioedema States. <i>Pharmaceuticals</i> , 2020, 13, 201.	3.8	5
51	Incidence of hypotension and acute hypotensive transfusion reactions following platelet concentrate transfusions. <i>Vox Sanguinis</i> , 2016, 110, 150-158.	1.5	4
52	Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor <i>XIII</i> A subunit; novel approach to the diagnosis and classification of anti-factor XIII antibodies. <i>Haemophilia</i> , 2017, 23, 590-597.	2.1	4
53	Thrombopoietin levels in Quebec platelet disorder: Implications for the mechanism of thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , 2018, 40, e33-e34.	1.3	4
54	Confounding effect of therapeutic protamine and heparin levels on routine and special coagulation testing. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 60-64.	1.0	4

#	ARTICLE	IF	CITATIONS
55	A full molecular picture of <i>F8</i> intron 1 inversion created with optical genome mapping. <i>Haemophilia</i> , 2021, 27, e638-e640.	2.1	4
56	Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2947-2956.	3.8	4
57	Magnetic resonance imaging in boys with severe hemophilia A: Serial and end-of-study findings from the Canadian Hemophilia Primary Prophylaxis Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12565.	2.3	4
58	Picomolar Sensitivity Analysis of Multiple Bradykinin-Related Peptides in the Blood Plasma of Patients With Hereditary Angioedema in Remission: A Pilot Study. <i>Frontiers in Allergy</i> , 2022, 3, 837463.	2.8	3
59	Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e274-e276.	1.3	2
60	Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating Quebec Platelet Disorder. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1464-1466.	1.7	2
61	Acquired haemophilia A and concomitant factor XIII consumption. <i>Haemophilia</i> , 2019, 25, e180-e183.	2.1	1
62	The diagnosis of a haemophilia A carrier over 2 decades. <i>Haemophilia</i> , 2021, 27, e133-e136.	2.1	1
63	Patterns of joint damage in severe haemophilia A treated with prophylaxis. <i>Haemophilia</i> , 2021, 27, 666-673.	2.1	1
64	Evaluation of anti-factor VIII antibodies in haemophilia A subjects switching products following a provincial tender. <i>Haemophilia</i> , 2022, 28, .	2.1	1
65	Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes. <i>Haemophilia</i> , 2019, 25, e113-e117.	2.1	0
66	A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma). <i>Haemophilia</i> , 2021, 27, e530-e533.	2.1	0
67	Immune tolerance induction using Fc-fusion-protein recombinant factor IX in severe haemophilia B. <i>Haemophilia</i> , 2021, 27, e776-e779.	2.1	0
68	Initial Clinical Presentation and Predictors of Thrombotic Thrombocytopenic Purpura in Quebec. <i>Blood</i> , 2021, 138, 4224-4224.	1.4	0
69	Incidence of Thrombotic Microangiopathies in Quebec: An 8-Year Overview from a Laboratory Centralizing Adams-13 Testing. <i>Blood</i> , 2021, 138, 4222-4222.	1.4	0
70	Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients. <i>Bioanalysis</i> , 2022, 14, 223-240.	1.5	0